The Protective Roll of Rosuvastatin on Chronic Heart Failure in Rats With its Effect on Asymmetric Dimethylarginine Metabolic Pathway
10.3969/j.issn.1000-3614.2014.09.021
- VernacularTitle:瑞舒伐他汀对慢性心力衰竭大鼠的心脏保护作用及其对非对称二甲基精氨酸代谢通路的影响
- Author:
Aiqin XIONG
;
Ping MA
;
Junmei LIU
;
Yehua XU
;
Yang WANG
;
Qingbin XU
- Publication Type:Journal Article
- Keywords:
Rosuvastatin;
Isoproterenol;
Chronic heart failure;
Asymmetric dimethylarginine;
Protein arginine methyltransferases 1;
Dimethylarginine dimethylamine hydrolase 2
- From:
Chinese Circulation Journal
2014;(9):743-747
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the protection roll of rosuvastatin on chronic heart failure (CHF) in rats with its effect on asymmetric dimethylarginine (ADMA) metabolic pathway.
Methods: A total of 36 male SD rats were randomly divided into 3 groups, n=12 in each group. Isoproterenol (ISO) group, the rats received ISO subcutaneous injection (5mg·kg·d) for 7 days to establish CHF model, and then received normal saline gavage administration for 7 days. Rosuvastatin (ROS) treatment group, the rats received ISO with ROS for 7 days, then continuously receiving ROS until 14 days. Normal control group, the rats received saline gavage administration for 7 days. The related serum index and haemodynamic parameters were examined, myocardial pathological changes were observed and the relevant protein expression was measured by Western blot analysis.
Results: Compared with Normal control group, ISO group had obviously increased troponin (cTn I), serum ADMA,-LVdP/dtmin, all P<0.01, and decreased left ventricular systolic pressure (LVSP), heart rate, arterial SP, mean arterial pressure, +LVdP/dtmax, all P<0.01. Compared with ISO group, ROS treatment group showed signiifcantly decreased BNP, cTn I, ADMA , -LVdP/dtmin, all P<0.01, and increased LVSP, heart rate, arterial SP, mean arterial pressure,+LVdP/dtmax, all P<0.01. Compared with Normal control group, ISO group had increased expression of protein arginine methyltransferases 1 (PRMT1), decreased expression of dimethyl- arginine dimethylaminohydrolase 2 (DDHA2), both P<0.01. Compared with ISO group, ROS treatment group showed decreased expression of PRMT1, P<0.01 and similar expression DDHA2, P>0.05.
Conclusion: Rosuvastatin has the protective roll on ISO induced CHF in rats, which might be related to decreased serum levels of cTn I, BNP and ADMA metabolic pathway regulation.
